The company’s market cap is $131.5 million.
Dominari Securities and Revere Securities are the underwriters for the IPO.
Jupiter Neurosciences, Inc. is a pharmaceutical R&D company focused on neuro-inflammation treatments. Their main product, JOTROL, uses a patented micellar technology to enhance the absorption of resveratrol. It comes in softgel capsules, each containing 100mg of resveratrol. Pre-clinical trials showed JOTROL has better bioavailability compared to other forms of resveratrol. A Phase I study in healthy volunteers showed promising results and will guide future clinical trials for various conditions, primarily targeting Parkinson’s Disease and other rare diseases.
The company plans to use IPO proceeds to start a Phase II trial for JOTROL in Parkinson’s patients, expand in Southeast Asia, and enhance manufacturing processes. They have successfully completed pre-clinical trials and a Phase I trial to assess safety.
On May 23, 2024, a U.S. Senate bill to end Parkinson’s Disease was passed, highlighting growing interest in JOTROL, especially in Asia due to resveratrol’s acceptance in traditional herbal medicine. Recent collaborations aim to improve their presence in the Southeast Asian market.
JOTROL aims to deliver effective doses of resveratrol without gastrointestinal side effects. The company secured $1.76 million from the National Institute on Aging for its Phase I study and will pursue additional grants for future trials.
Founded in 2016, Jupiter Neurosciences, Inc. is located in Jupiter, Florida, and currently has 4 employees. For more information, visit their website.
Receive Daily News & Ratings for Jupiter Neurosciences Inc. – Enter your email below for a daily summary of the latest news and ratings from MarketBeat.com’s FREE daily email newsletter.
`
